Company Overview and News

1
Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?

2018-09-12 zacks
On Sep 11, shares of Genomic Health, Inc. (GHDX - Free Report) scaled a 52-week high of $64.61, closing the session marginally lower at $64.46.
MASI AMED ISRG GHDX

3
Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS

2018-09-06 globenewswire
Mechelen, Belgium, 6 September 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces its business highlights and financial results for the first half of 2018, prepared in accordance with the IAS 34 Interim Financial Reporting as adopted by the European Union. Furthermore, the Company provides it updated outlook for the full year 2018.
MKGAF MKGAY TMO GHDX

 
Biocartis Group NV: BIOCARTIS KONDIGT H1 2018 RESULTATEN AAN

2018-09-06 globenewswire
Mechelen, België, 6 september 2018 - Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag zijn belangrijkste bedrijfs- en financiële resultaten aan voor de eerste jaarhelft van 2018, die zijn opgesteld overeenkomstig de IAS 34 'Tussentijdse Financiële Verslaggeving' zoals toegepast binnen de EU. De Vennootschap kondigt verder ook geactualiseerde vooruitzichten aan voor de rest van 2018.
GHDX

6
Here's Why You Should Invest in Genomic Health (GHDX) Now

2018-08-29 zacks
Genomic Health, Inc. (GHDX - Free Report) has been gaining investor confidence on stellar results over an extended period. Over the past year, the company’s share price has outperformed its industry. The stock has gained 91.8% against the industry’s 11.8% fall. Also, the company has fared better than the S&P 500’s 18.4% rise.
MASI ISRG URBN GHDX

 
GHDX / Genomic Health, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
ghdx_Current folio_10Q Table of Contents
GHDX

 
Genomic Health's (GHDX) CEO Kim Popovits on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good afternoon. My name is James, and I will be your conference operator today. At this time, I would like to welcome everyone to Genomic Health’s Second Quarter 2018 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be provided at that time. [Operator Instructions] As a reminder, this call is being recorded.
DB GHDX

2
Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates

2018-08-03 zacks
Genomic Health, Inc. (GHDX - Free Report) reported second-quarter 2018 adjusted earnings per share (EPS) of 26 cents against the year-ago adjusted net loss of 8 cents per share. The bottom line also exceeded the Zacks Consensus Estimate of 7 cents.
ALGN CY ISRG CHE GHDX

1
Genomic Health (GHDX) Tops Q2 Earnings and Revenue Estimates

2018-08-03 zacks
Genomic Health (GHDX - Free Report) just came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.
CCS STRL DATA ENSG GHDX

 
GHDX / Genomic Health, Inc. 8-K (Current Report)

2018-08-02 sec.gov
ghdx_Current_folio_8K
GHDX

18
Here's Why You Should Hold Onto Cardinal Health Stock Now

2018-07-23 zacks
With a market capitalization of approximately $15.16 billion, Cardinal Health, Inc’s (CAH - Free Report) Medical and Pharmaceutical offerings lend the company with a competitive edge in the MedTech space. The company offers industry expertise and a solid portfolio of safe medical products like Bathroom Safety, Mobility, and Exam Room Equipment products. However, the company has been facing sluggishness in the exam-gloves unit lately.
UBS SYK CAH ABMD CVS GHDX ULSGF

 
Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label

2018-07-20 zacks
Eli Lilly and Company (LLY - Free Report) announced that it has updated its diabetes drug Trulicity’s label to include data from a new study, which showed that the GLP-1 receptor agonist was effective in type II diabetes patients with moderate to severe chronic kidney disease (CKD).
VNDA GHDX IQV

2
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

2018-07-20 zacks
Abbott (ABT - Free Report) has been gaining investors’ confidence on consistently positive results. Over the past six months, the company’s share price has outperformed its industry. The stock has gained 7.1%, compared to the industry’s 5.3%. The company has also fared better than the 0.3% decline of the S&P 500 market.
ALGN BAX GHDX

1
Can the Rally in Genomic Health (GHDX) Shares Continue?

2018-07-20 zacks - 1
Genomic Health, Inc. (GHDX - Free Report) has been on the move lately as the stock has risen by 13.5% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue?
GHDX

6
AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 11.8% in Session

2018-07-20 zacks - 3
AVEO Pharmaceuticals, Inc. (AVEO - Free Report) was a big mover last session, as the company saw its shares rise more than 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $1.95-$2.90 in the past one-month time frame, showed a sharp increase yesterday. The move came after the company issued statement on its revised guidance regarding the timing of top-line data from the TIVO-3 study.
CFIN KDP CIWV AVEO RF GHDX

2
Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues

2018-07-20 zacks
Intuitive Surgical, Inc (ISRG - Free Report) reported adjusted earnings of $2.76 per share in the second quarter of 2018, which beat the Zacks Consensus Estimate of $2.48. Adjusted Earnings improved 38% year over year.
ALGN KDP ISRG GHDX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

19h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

19h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

21h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to GHDX / Genomic Health, Inc. on message board site Silicon Investor.

Genomic Health: predicting the course of an individualu0027s can Genomic Health: predicting the course of an individualu0027s can Genomic Health: predicting the course of an individualu0027s can
CUSIP: 37244C101